Related Experiment Video
Updated: Jun 29, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target
Alejandro Manzanares-Guzmán1, Pavel H Lugo-Fabres2, Tanya A Camacho-Villegas2
1Unidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Guadalajara 44270, Mexico.
Abstract:
Glioblastoma is the most prevalent and fatal form of primary brain tumors. New targeted therapeutic strategies for this type of tumor are imperative given the dire prognosis for glioblastoma patients and the poor results of current multimodal therapy. Previously reported drawbacks of antibody-based therapeutics include the inability to translocate across the blood-brain barrier and reach intracellular targets due to their molecular weight. These disadvantages translate into poor target neutralization and cancer maintenance. Unlike conventional antibodies, vNARs can permeate tissues and recognize conformational or cryptic epitopes due to their stability, CDR3 amino acid sequence, and smaller molecular weight. Thus, vNARs represent a potential antibody format to use as intrabodies or soluble immunocarriers. This review comprehensively summarizes key intracellular pathways in glioblastoma cells that induce proliferation, progression, and cancer survival to determine a new potential targeted glioblastoma therapy based on previously reported vNARs. The results seek to support the next application of vNARs as single-domain antibody drug-conjugated therapies, which could overcome the disadvantages of conventional monoclonal antibodies and provide an innovative approach for glioblastoma treatment.
Insights
Novel antibody fragments called variable new antigen receptors (vNARs) show promise for treating glioblastoma. Their unique properties allow them to target cancer cells effectively, offering a new therapeutic avenue for this aggressive brain tumor.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Glioblastoma is an aggressive primary brain tumor with a poor prognosis and limited treatment options.
- Conventional antibody therapeutics face challenges in crossing the blood-brain barrier and reaching intracellular glioblastoma targets.
- Limitations of current multimodal therapies necessitate the development of novel therapeutic strategies.
Purpose of the Study:
- To review intracellular pathways driving glioblastoma proliferation, progression, and survival.
- To identify potential new targeted glioblastoma therapies using variable new antigen receptors (vNARs).
- To explore vNARs as a potential therapeutic modality to overcome limitations of conventional antibodies.
Main Methods:
- Comprehensive review of existing literature on glioblastoma intracellular pathways.
- Analysis of the properties of vNARs, including stability, CDR3 sequence, and molecular weight.
- Evaluation of vNARs' potential for tissue permeation and epitope recognition.
Main Results:
- vNARs possess characteristics (stability, small size) enabling tissue penetration and intracellular target access.
- vNARs can recognize conformational or cryptic epitopes, offering broader targeting capabilities.
- vNARs represent a promising antibody format for intrabodies or soluble immunocarriers.
Conclusions:
- vNARs offer a potential innovative approach for glioblastoma treatment by overcoming conventional antibody limitations.
- vNARs could be developed as single-domain antibody drug-conjugated therapies for targeted glioblastoma treatment.
- Further research into vNARs supports their application in novel glioblastoma therapeutic strategies.
